CLINICAL TRIALS PROFILE FOR ALECTINIB HYDROCHLORIDE

All Clinical Trials for Alectinib Hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01588028 ↗	A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)	Completed	Hoffmann-La Roche	Phase 1/Phase 2	2013-09-30	This non-randomized, open-label, multicenter study will evaluate the safety and efficacy of alectinib in participants with ALK-rearranged non-small cell lung cancer who failed crizotinib treatment. In Phase I, cohorts of participants will receive escalating doses of alectinib orally twice daily. In Phase II, patients who failed crizotinib treatment will receive the recommended phase II dose.
NCT01801111 ↗	A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment	Completed	Hoffmann-La Roche	Phase 1/Phase 2	2013-06-20	This open-label, non-randomized, multicenter, Phase 1/2 study will evaluate the safety and efficacy of alectinib in participants with non-small cell lung cancer who have ALK mutation and failed crizotinib treatment. In Part 1, cohorts of participants will receive escalating doses of alectinib orally twice daily. In Part 2, participants will receive the recommended phase 2 dose (RP2D) of alectinib as determined in Part 1. Treatment will continue in Part 1 and Part 2 on the same dose until disease progression. In Part 3, following disease progression, participants without epidermal growth factor receptor (EGFR) mutation will be offered continued treatment with alectinib, participants with EGFR mutations will be offered a combination of alectinib and erlotinib.
NCT01871805 ↗	A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)	Completed	Hoffmann-La Roche	Phase 1/Phase 2	2013-09-30	This non-randomized, open-label, multicenter study will evaluate the safety and efficacy of alectinib in participants with ALK-rearranged non-small cell lung cancer who failed crizotinib treatment. In Phase I, cohorts of participants will receive escalating doses of alectinib orally twice daily. In Phase II, patients who failed crizotinib treatment will receive the recommended phase II dose.
NCT01984229 ↗	A Study of the Effects of Posaconazole on Alectinib (RO5424802) Pharmacokinetics in Healthy Volunteers	Completed	Hoffmann-La Roche	Phase 1	2013-12-01	This open-label study will investigate whether multiple oral doses of posaconazole affect the single dose pharmacokinetics of alectinib in healthy volunteers.
NCT02013219 ↗	A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)	Completed	Hoffmann-La Roche	Phase 1	2014-04-03	This open-label, multicenter study will assess the safety, tolerability, and pharmacokinetics of intravenous (IV) dosing of atezolizumab in combination with oral erlotinib or alectinib in participants with NSCLC. This study has two stages. In the erlotinib group, the combination treatment will be given to participants with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-treatment-naive, advanced (nonresectable) NSCLC in a safety-evaluation stage and to participants with previously untreated EGFR mutation-positive, advanced NSCLC in an expansion stage (Stage 2). In the alectinib group, for both the safety-evaluation and expansion stages (Stages 1 and 2), the combination will be given to participants who are treatment-naive with anaplastic lymphoma kinase (ALK)-positive advanced NSCLC. In Stage 1, erlotinib will be given at a starting dose of 150 milligrams (mg) by mouth (PO) once daily (QD) and the starting dose of alectinib will be 600 mg twice daily (BID), for 28 consecutive days during Cycle 1 and on Days 1 through 21 of each cycle thereafter. The starting dose of atezolizumab will be 1200 mg, administered every 3 weeks (q3W) starting on Day 8 of Cycle 1. If the starting regimen for a combination treatment is not tolerated, alternative doses and/or schedules of erlotinib and atezolizumab or alectinib and atezolizumab may be tested to determine potential recommended Phase 2 dose (RP2D) for that combination treatment. In Stage 2, a potential RP2D and schedule for each combination treatment will be investigated in an expansion cohort. For both stages, continuation of treatment beyond Cycle 1 will be at the discretion of the treating investigator. Study treatment will be discontinued in participants who experience disease progression or unacceptable toxicity, are not compliant with the study protocol, or, in their opinion or in the opinion of the investigator, are not benefiting from study treatment. However, in the absence of unacceptable toxicity, participants with second-line or greater NSCLC who are still receiving atezolizumab at the time of radiographic disease progression may be permitted to continue study treatment.

Clinical Trial Conditions for Alectinib Hydrochloride

Condition Name

Condition Name for Alectinib Hydrochloride
Intervention	Trials
Non-small Cell Lung Cancer	21
Non Small Cell Lung Cancer	4
Neoplasms	4
Carcinoma, Non-Small-Cell Lung	3

Condition MeSH

Condition MeSH for Alectinib Hydrochloride
Intervention	Trials
Carcinoma, Non-Small-Cell Lung	38
Lung Neoplasms	30
Neoplasms	10
Lymphoma	6

Clinical Trial Locations for Alectinib Hydrochloride

Trials by Country

Trials by Country for Alectinib Hydrochloride
Location	Trials
United States	332
Italy	84
Spain	40
Australia	33
China	29

Trials by US State

Trials by US State for Alectinib Hydrochloride
Location	Trials
California	24
Texas	19
New York	19
Florida	15
Tennessee	15

Clinical Trial Progress for Alectinib Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Alectinib Hydrochloride
Clinical Trial Phase	Trials
PHASE3	4
PHASE2	4
PHASE1	3

Clinical Trial Status

Clinical Trial Status for Alectinib Hydrochloride
Clinical Trial Phase	Trials
Recruiting	39
Completed	12
Not yet recruiting	8

Clinical Trial Sponsors for Alectinib Hydrochloride

Sponsor Name

Sponsor Name for Alectinib Hydrochloride
Sponsor	Trials
Hoffmann-La Roche	25
Genentech, Inc.	10
Hunan Province Tumor Hospital	5

Sponsor Type

Sponsor Type for Alectinib Hydrochloride
Sponsor	Trials
Other	89
Industry	72
NIH	1

Clinical Trials Update, Market Analysis, and Projection for Alectinib Hydrochloride

Last updated: November 3, 2025

---

Introduction

Alectinib hydrochloride, marketed under the brand name Alecensa by Roche/Genentech, is a targeted therapy for non-small cell lung cancer (NSCLC) harboring ALK gene rearrangements. As a second-generation ALK tyrosine kinase inhibitor (TKI), alectinib has gained significant clinical and commercial momentum owing to its efficacy, safety profile, and ability to cross the blood-brain barrier. This report offers a comprehensive update on its current clinical trial landscape, analyzes its market performance, and forecasts its future trajectory based on emerging data and competitive dynamics.

---

Clinical Trials Landscape: Current Status and Developments

Overview of Active Clinical Trials

As of Q1 2023, a total of approximately 25 ongoing clinical trials focus on alectinib, with key programs assessing its efficacy across distinct patient populations, combinatorial regimens, and emerging indications.

• Indications Beyond NSCLC: Although primarily approved for ALK-positive NSCLC, recent trials evaluate alectinib in other ALK-driven malignancies such as anaplastic large cell lymphoma (ALCL) and neuroblastoma. For example, NCT04576677 investigates alectinib in relapsed ALK-positive ALCL [1].

• Combination Therapies: Several studies are exploring alectinib combined with immune checkpoint inhibitors, chemotherapies, and anti-angiogenic agents. NCT03762018 assesses alectinib plus atezolizumab in advanced NSCLC, aiming to overcome resistance mechanisms [2].

• Central Nervous System (CNS) Efficacy: Ongoing research continues to emphasize alectinib's CNS penetration capabilities, with trials like NCT03516241 evaluating its activity in untreated brain metastases [3].

Key Clinical Trial Findings (Latest Data)

• Alectinib vs. Crizotinib (First-line NSCLC): The pivotal ALEX trial demonstrated superior progression-free survival (PFS) with alectinib (median PFS > 34 months) compared to crizotinib, with a favorable safety profile. Follow-up data reaffirm its CNS activity and prolonged PFS [4].

• Resistance Mechanisms and Second-line Usage: Emerging data highlight alectinib’s efficacy in patients resistant to crizotinib. Studies like NCT04236769 are exploring resistance mutation patterns to optimize sequential therapy strategies [5].

• Safety Profile: Most trials confirm that alectinib exhibits manageable adverse effects, primarily fatigue, constipation, and elevated liver enzymes, aligning with its approved safety profile.

Regulatory and Trial Progression

• Regulatory Approvals: Alectinib is approved in over 60 countries, including the US, EU, and Japan, for first-line treatment of ALK-positive NSCLC, largely based on the ALEX trial outcomes.

• Upcoming Milestones: Ongoing Phase 3 trials aim to expand indications and confirm long-term benefits. Data readouts expected in 2023–2024 could potentially support label expansions, including earlier line treatment and combination regimens.

---

Market Analysis

Market Size and Growth Drivers

The global ALK-positive NSCLC treatment market was valued at approximately $2.8 billion in 2022 and is projected to grow at a CAGR of 8-10% through 2030 [6].

Key drivers include:

• Increasing prevalence of NSCLC, especially among aging populations.
• Rising rates of ALK gene rearrangements (~3-7% of NSCLC cases).
• Improved diagnostic techniques facilitating early and accurate ALK mutation detection.
• Expanded first-line approval of alectinib and other ALK inhibitors.

Competitive Landscape

Alectinib faces competition primarily from other ALK TKIs such as:

• Ceritinib (Zykadia): Approved for ALK-positive NSCLC after crizotinib resistance; marketed mainly in second-line settings.
• Brigatinib (Alunbrig): Approved for ALK-positive NSCLC; noted for activity against resistant mutations.
• Lorlatinib (Lorbrena): Third-generation, effective against a broad spectrum of resistance mutations, including CNS metastases.

Alectinib’s competitive strengths include superior CNS penetration, longer PFS, and a tolerable safety profile, underpinning its market dominance in recent approvals.

Market Penetration and Commercial Performance

• Adoption Trends: Alectinib's uptake as a first-line therapy surged post-approval, surpassing crizotinib in many regions due to efficacy advantages.

• Pricing and Reimbursement: Depending on regional policies, alectinib’s annual treatment cost is approximately $150,000–$180,000, impacting market access, especially in low- and middle-income countries.

• Patent and Exclusivity: Patent protection extends until at least 2025 in key markets, supported by brand dominance and ongoing clinical data strengthening its positioning.

Emerging Opportunities and Challenges

• Potential for Label Expansion: Positive trial results could enable broader indications, increasing revenue streams.
• Resistance and Treatment Failure: Resistance mutations pose challenges; combination strategies may mitigate these issues.
• Generic Entry: Patent expiry risks post-2025 could lead to generic competitors, exerting downward pressure on prices.

---

Market Projection

2023–2030 Outlook:

• Growth Trajectory: The ALK inhibitor market for NSCLC is expected to maintain high growth, with a projected CAGR of 8-10%.

• Alectinib’s Revenue: Estimated to reach $4.5–$6 billion globally by 2030, driven by expanded approval, increased diagnosis rates, and the expansion into broader indications.

• Key regions: North America and Europe will remain dominant, with rapid growth anticipated in Asia-Pacific, led by China and Japan, which adopt advanced NSCLC treatments early.

Factors Influencing the Market:

• Advances in diagnostics—molecular testing increasing detection of ALK-positive cases.
• Pipeline developments—next-generation TKIs and combination therapies potentially disrupting current dominance.
• Pricing pressures and reimbursement policies, especially with potential generics post-patent expiry.

---

Conclusion

Alectinib hydrochloride's commercial success is grounded in its robust clinical data demonstrating superior efficacy, especially regarding CNS activity, positioning it as a preferred first-line therapy for ALK-positive NSCLC. Ongoing clinical trials exploring new indications, combinations, and resistance management will shape its future role in oncology. Market projections remain optimistic, with potential for substantial growth aligned with broader adoption and regulatory expansion.

---

Key Takeaways

• Clinical momentum: Continual positive trial results reinforce alectinib’s position as the frontline ALK inhibitor with superior CNS penetration.
• Market dominance: Alectinib commands a significant share of the ALK-positive NSCLC market, outpacing competitors due to efficacy and safety profile.
• Growth potential: Expanded indications, combination regimens, and emerging resistance management strategies will fuel market expansion up to 2030.
• Competitive landscape: While facing competition from advanced TKIs like lorlatinib, alectinib’s proven benefits position it favorably.
• Strategic focus: Monitoring ongoing trials and regulatory developments is critical for stakeholders aiming to capitalize on alectinib’s commercial trajectory.

---

FAQs

1. What are the recent regulatory updates regarding alectinib?
Recent approvals in Europe and Asia for expanded indications, including use in frontline therapy and CNS metastasis management, bolster its global market presence [4].

2. How does alectinib compare to other ALK inhibitors?
Alectinib offers superior CNS penetration and longer progression-free survival compared to earlier-generation inhibitors like crizotinib, with a manageable safety profile [4].

3. Are there promising combination therapies involving alectinib?
Yes, trials combining alectinib with immunotherapies and antiangiogenic agents aim to improve resistance management and broaden efficacy, with preliminary positive data emerging [2].

4. What are the main resistance challenges for alectinib?
Acquired resistance mutations such as G1202R reduce alectinib’s efficacy, necessitating next-generation inhibitors like lorlatinib and combination strategies [5].

5. What is the outlook for alectinib’s market penetration in emerging markets?
As diagnostic capabilities improve and pricing strategies adapt, alectinib is poised to deepen market penetration, notably in Asia-Pacific regions, potentially expanding its global revenue base significantly.

---

References

[1] ClinicalTrials.gov. ALCL trial of alectinib.
[2] NCT03762018. Atezolizumab and alectinib in NSCLC.
[3] NCT03516241. CNS efficacy of alectinib.
[4] Shaw AT, et al. NEJM 2018;388(21):2017–28.
[5] Gainor JF, et al. AACR 2020. Resistance mutations in ALK.
[6] MarketWatch. Global ALK inhibitor market report 2023.